Q&A with Pulmocide CEO Garth Rapeport – Why Pulmocide is developing targeted lung therapy.

7th August 2019 in Portfolio News

Author: Jess Young

Publication: SWNS

In a Q&A interview, Garth Rapeport, CEO of SV portfolio company Pulmocide, explains why the company is developing inhaled medications for viral and fungal infections and offers advice to startup biopharma companies based on his experience from working with firms like SV.

View the article

PROUD SIGNATORIES

We invest in talented innovators. We strongly adhere to the view that diversity, including under-represented groups, strongly adds to success. If you are an entrepreneur seeking investment and a partner who can help you to build your business, we would love to hear from you. Please get in contact with our team.